Abbott wins the bidding for Solvay’s drug unit – Abbott Laboratories will announce today the €5bn ($7.3bn) acquisition of Solvay’s pharmaceutical company, bringing a five-month takeover battle to an end and highlighting continued consolidation in the industry. The US drugmaker beat UCB of Belgium and Nycomed of Switzerland to buy the division, which is valued at between €4.5bn and €5bn…more
The Medicines Company gets encouraging results from Angiomax study – The Medicines Company today announced the presentation of 2-year clinical results from the landmark HORIZONS-AMI Trial. The trial showed that patients who had suffered the most severe form of heart attack were significantly less likely to suffer cardiac death and had better overall survival if treated with Angiomax® (bivalirudin) while undergoing angioplasty compared with those treated with heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) during angioplasty...more
Merck‘s diabetes drug Januvia with pancreatitis link? Merck says no, but FDA concerned.
Social Media Strategy. We do that. If your company is wrestling with how to move forward with social media, contact us (stevew at impactiviti dot com, or phone at 973-947-7429) to talk.
Is the Apple iPhone 3GS good enough to record the video of an entire conference presentation? Well, yes, it kinda can. Here are the results of my little experiment, from last week’s PharmaMed conference.
Coming up next month:
Oct. 19-21 – eXL’s Digital Pharma conference, Bridgewater, NJ. This event will be quite progressive, with more of an informal “unconference” format to maximize interaction. I’ll be co-leading a pre-conference workshop on the 19th on social media, and live-blogging/Twittering. Here’s a discount code for 15% your registration: P615WOO
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Connect with Steve Woodruff